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Imatinib (STI571) has been shown to induce sustained cytogenetic responses in 
some patients with accelerated phase CML.l,2 The median time to achieve a 
cytogenetic response was less than 3 months and survival without progression was 
poor in patients who did not achieve a major cytogenetic response. The Seattle 
team has recently developed a low- intensity nonmyeloablative conditioning 
regimen combining low dose TBI and fludarabine. They observed a high response 
rate in chronic phase CML but results in accelerated phase were disappointing with 
high rate of graft rejection. 3 This report demonstrates the feasibility of combining 
nonmyeloablative stem cell transplantation and Imatinib in accelerated phase CML. 
A 59-yr-old man was diagnosed in August 2001 with accelerated phase CML (more 
than 20% basophils in his blood). After one month on hydroxyurea, Imatinib was 
started at 600 mg/Day. Bone marrow analysis 3 months later evidenced an 
hematologic remission with a minor cytogenetie response (persistence of 74% of 
Ph+ metaphases). The patient underwent an allogeneic peripheral blood stem cell 
(PBSC) transplantation from his HLA-identieal sister after a nonmyeloablative 
conditioning regimen eombining 2 Gy total body irradiation and 90 mg/m2 
fludarabine, as previously reported. 3,4 Imatinib was interrupted at the time of 
transplant to avoid its potential toxie effect on normal hematopoiesis. 5 Post-
transplant immunosuppression was earried out orally with cyclosporine and 
mycophenolate mofetil and the patient was followed in the outpatient setting. On 
Day 28, his blood eount was 16.5 x 109/L with 10% basophils and bone marrow 
analysis showed a hematologic relapse with 21/25 abnormal [46 XY, t(9;22)J and 
4/25 normal (46 XX) metaphases. Bone marrow and peripheral blood CD3 and 
CD13 chimerism (measured with FISH as previously reported)4 were 13%, 14% and 
13%, respectively. Imatinib (600 mg/Day) therapy was restored on Day 28 and the 
patient achieved a normal blood count 14 da ys later. Bone marrow analysis on Day 
40 showed a minor response (60% PH-positive metaphases). The patient did not 
experience acute GVHD and received a first don or lymphocyte infusion (DU) on Day 
60 because of poor T cell chimerism. We decided to maintain cyclosporin during DU 
according to Zaucha et al. who demonstrated in the Seattle dog model that 
increasing the duration of posttransplantation immunosuppression with CSP From 35 
to 100 days favorably influenced stable donor engraftment. 6 Imatinib was then 
reduced to 400 mg/Day because of fluid retention. Bone marrow analysis on Day 
100 revealed a hematologic remission with a major cytogenetic response (3/31 XY 
metaphases with t(9;22) and 28/31 XX metaphases). A second DU was given on 
Day 150. The patient did not experience acute or chronie GVHD nor severe 
cytopenia. Bone marrow analysis on Day 180 after the transplant showed a 
complete eytogenetie response (21/21 XX metaphases) that was eonfirmed on Day 
250 (26/26 XX metaphases) with no BCR-ABL rearrangement on FISH analysis 
(although rt-PCR remained positive). CD3 and CD13 chimerism evolutions are 
shown in the Figure 1. 
Imatinib therapy for CML relapse after allogeneic HSCT has been shown to induee 
complete eytogenetic responses and complete restoration of donor-type 
hematopoiesis in some patients,?-9 Our patient had a hematologic relapse and only 
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13% T cell chimerism on day 28, a value strongly associated with a high incidence 
of graft rejection, even with additional DU.3,lO Althought it cannot be totally 
excluded that DU alone could still have achieved it, this suggests that Imatinib 
therapy followed by DU permitted to avoid graft rejection by rapidly suppressing 
Ph-derived hematopoiesis. Furthermore, whereas a similar course on 600 mg/day 
did not produce a significant cytogenetic response before the transplant, normal 
metaphases of recipient origin disappeared by day 180 and a complete cytogenetic 
response was achieved with a 3-mo course of 400 mg/day Imatinib therapy. This 
strongly suggests that some GVL effect also occurred under Imatinib therapy. 
Further studies are needed to confirm this preliminary result and to study the 
impact of Imatinib on the achievement of a full donor T cell chimerism as weil as on 
the GVL effect. ll 
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